Spyre Therapeutics, Inc. SYRE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s operating cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported operating cash flow of -$57.37M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s operating cash flow decreased by 40.0% year-over-year, from -$40.99M to -$57.37M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s operating cash flow has grown at a 32.0% compound annual growth rate (CAGR), from -$55.8M to -$169.25M.
- What does operating cash flow mean?
- The net cash flow resulting from the company's day-to-day business operations.
- How do you interpret operating cash flow?
- Higher values indicate a self-sustaining business model, while negative values indicate a reliance on external funding.
- How does operating cash flow compare across companies?
- Essential benchmark for all companies; negative in early-stage biotech, positive in mature firms.